TY - JOUR T1 - Clinical management and discontinuation of treatment in patients with recent onset rheumatoid arthritis in a rheumatology consultation JO - Reumatología Clínica (English Edition) T2 - AU - Rosales Rosado,Zulema AU - Font Urgelles,Judit AU - Hernández Rodríguez,Isabel AU - León Mateos,Leticia AU - Abásolo Alcázar,Lydia AU - Jover Jover,Juan Ángel SN - 21735743 M3 - 10.1016/j.reumae.2020.08.003 DO - 10.1016/j.reumae.2020.08.003 UR - https://reumatologiaclinica.org/en-clinical-management-discontinuation-treatment-in-articulo-S2173574321001064 AB - IntroductionThe treatment of Rheumatoid Arthritis (RA) has changed dramatically in recent years, especially with the use of disease modifying drugs (DMARDs). Data on the management of this disease in clinical trials are abundant, but not so in real life. The aim of our study is to describe the management of an early RA cohort in daily clinical practice, especially DMARD discontinuations and reasons. MethodsA retrospective observational study of patients with RA diagnosed between 01/07 and 12/14 followed up to 01/17, using >1 DMARD ≥ 3 months. Variables: sociodemographic, clinical, treatment, DMARD discontinuation and reason. Descriptive analysis of sociodemographic, clinical and treatment characteristics. Discontinuation incidence rate (DIR) due to survival techniques, expressed in 100 patients*year with 95% confidence interval. Results814 patients were included with 2388 courses of treatment, 77% women, mean age 57.5 years. First course: monotherapy (92.75%), especially Methotrexate (56.06%). In later courses there was increased combined therapy and use of biologicals (mainly Etanercept). There were 1094 discontinuations (29.5 [27.8–31.3]). The DIR was higher for adverse events (15.9 [14.7–17.3]), biologicals (49.6 [43.1–57.2]) and combined therapy. The DMAR with the lowest DIR was MTX (25.8 [23.8–28.1]). ConclusionMethotrexate was the most used drug, biologicals increased throughout the follow-up, the most frequent being Etanercept. The DMARD DIR was 29*100 patients per year, mainly due to adverse events. It seems to be higher in the therapies that include biologicals and combined therapies. MTX is the drug with the lowest DIR. ER -